1. Scrip
  2. >>Business
  3. >>Financing

Finance Watch: Biopharma VC Funding Dips In Q3, Remains Relatively High For Year

With Exits Down, So Are New Financings

 
• By Mandy Jackson

Private Company Edition: Third quarter venture capital funding for biopharmaceutical firms fell from Q2, but activity remains near all-time highs year-to-date. Several companies announced VC financings in early October, including Ascidian, which launched with $50m in series A financing.

Finance Watch Private Company
• Source: Shutterstock

Venture capital investment dropped about 41% for biopharma firms for the third quarter from Q2, with 94 companies raising $4.5bn in Q3, down from 251 companies that raised $7.6bn in Q2, according to the Venture Monitor report from the National Venture Capital Association (NVCA) and Pitchbook. But despite the stark quarter-over-quarter decline, 2022 still is the third-highest VC fundraising year on record for the sector. With a year-to-date total of $23.8bn, 2022 falls behind the record-breaking years of 2020 and 2021, in which the industry raised $28.7bn and $38bn, respectively.

The biopharmaceutical industry experience is consistent with VC trends across all industries

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Financing

Finance Watch: Deerfield Closes $600m-Plus VC Fund; Gates Speeds Up Health Investments

 
• By Mandy Jackson

Private Company Edition: Deerfield’s third innovations fund will back therapeutics and other opportunities, the Gates Foundation – a sometimes funder of biotech firms – will spend $200bn over the next 20 years, and NewLimit raised a $130m series B round, among other financings.

HAYA Raises $65m To Take First Long Non-Coding RNA Program Into The Clinic

 
• By Mandy Jackson

HTX-001 targeting the long non-coding RNA known as Wisper is being developed for non-obstructive hypertrophic cardiomyopathy. HAYA partnered with Lilly last year in obesity.

Sanofi R&D Head’s Words Of Wisdom For Biotechs

 
• By Kevin Grogan

Houman Ashrafian tells delegates at Swiss Biotech Day that ‘literally only two things matter in our industry – target credentialing and differentiated pharmacology. The rest is execution.’

Switzerland Biopharma To Stay Strong Despite More Cash Going To US And China

 
• By Kevin Grogan

The sector is continuing to show resilience despite financial and market challenges.

More from Business